Prostrakan press release

ProStrakan Group plc
ProStrakan Announces FDA Acceptance of US Submission of Cellegesic™
(nitroglycerin) 0.4% Ointment
Galashiels, UK. 21st October 2009 – ProStrakan Group plc (LSE: PSK), the international
specialty pharmaceutical company, today announces that the US Food and Drug Administration (“FDA”) has confirmed acceptance for review of ProStrakan’s refiling of its New Drug Application (“NDA”) for Cellegesic™ (nitroglycerin) 0.4% Ointment for the treatment of moderate to severe pain associated with chronic anal fissures. This refiling was made in response to the Action Letter issued by the FDA for Cellegesic on 7th July Nitroglycerin-containing compounds are already recommended by a number of European and US clinical bodies for the pharmacological treatment of moderate to severe pain associated with chronic anal fissures, particularly as first line therapy, before resorting to surgery. Rectal use of nitroglycerin-containing compounds is well established in the US. Currently, these compounds are prepared at pharmacy outlets and there is therefore no assurance to the quality or strength of drug that the patient receives. Also, the safety and efficacy of these products have not been approved by the FDA. Subject to approval by the FDA, Cellegesic will be the first nitroglycerin product licensed in the US to address this In excess of 700,000 patients (Verispan PDDA MAT 03/08, ICD-9 565) in the US seek treatment for anal fissures each year. ProStrakan owns the global intellectual property rights to Cellegesic and the product forms an important part of the Company’s commercial strategy in Europe, where it has been approved and is marketed as Rectogesic, and in the US, where ProStrakan currently markets Sancuso®, its novel, transdermal patch for the prevention of chemotherapy-induced nausea and vomiting (CINV), through its exclusive Commenting on the US filing of Cellegesic, Dr Wilson Totten, Chief Executive of “The filing of Cellegesic is a further milestone in ProStrakan’s development and commercial expansion into the US. There are no currently approved products in the US for pain associated with chronic anal fissures and Cellegesic will fill this unmet need.”
Further enquiries:
Allan Watson, Chief Financial Officer Callum Spreng, Corporate Comms Jon Coles / Justine McIlroy
About ProStrakan

ProStrakan Group plc is a rapidly growing specialty pharmaceutical company engaged in
the development and commercialisation of prescription medicines for the treatment of
unmet therapeutic needs in major markets.
ProStrakan's head office is located in Galashiels in Scotland. The company’s development
capabilities are centred in Galashiels and Bedminster, New Jersey, USA. Sales and
marketing of ProStrakan's portfolio of products are handled by commercial subsidiaries in
the UK, US, France, Germany, Spain, Italy and other EU countries.



Quick Reference Chart for the WHO Medical Eligibility Criteria for Contraceptive Use – to initiate or continue use of combined oral contraceptives (COCs), depot-medroxyprogesterone acetate (DMPA), progestin-only implants, copper intrauterine device (Cu-IUD) CONDITION Implants Cu-IUD CONDITION Implants Cu-IUD Pregnancy Gestational trophoblastic Breastfeeding Persi

Managing contraceptive pill/drug patients, 14th edition

Managing Contraceptive Pill/Drug Patients , 14th edition By Richard P Dickey, MD, PhD in Pharmacology As therapists offering premarital counseling and sexual therapy, it is important to be aware of the hormonal impact of various oral contraceptives (OCs) and other contraceptive drugs. Because of the differences in the makeup of the components, each hormonal contraceptive has a different pat

Copyright © 2009-2018 Drugs Today